{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ureter+Neoplasms&page=2",
    "query": {
      "condition": "Ureter Neoplasms",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Ureter+Neoplasms&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T08:13:30.910Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00006376",
      "title": "R115777 in Treating Patients With Advanced Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter"
      ],
      "interventions": [
        {
          "name": "chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2000-03",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-07-22T08:13:30.910Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Tampa, Florida",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006376"
    },
    {
      "nct_id": "NCT04865939",
      "title": "Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urothelial Cancer of Renal Pelvis",
        "Urothelial Carcinoma Ureter"
      ],
      "interventions": [
        {
          "name": "sterile water irrigation",
          "type": "PROCEDURE"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 132,
      "start_date": "2021-11-29",
      "completion_date": "2031-11-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-07-22T08:13:30.910Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04865939"
    },
    {
      "nct_id": "NCT00479128",
      "title": "Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Urethral Cancer"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 80,
      "start_date": "2006-09-28",
      "completion_date": "2026-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-16",
      "last_synced_at": "2026-07-22T08:13:30.910Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00479128"
    },
    {
      "nct_id": "NCT00028860",
      "title": "Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Tulane University Health Sciences Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "2001-10",
      "completion_date": "2004-10",
      "has_results": false,
      "last_update_posted_date": "2013-07-10",
      "last_synced_at": "2026-07-22T08:13:30.910Z",
      "location_count": 1,
      "location_summary": "New Orleans, Louisiana",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00028860"
    },
    {
      "nct_id": "NCT00072150",
      "title": "Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Recurrent Bladder Cancer",
        "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Recurrent Urethral Cancer",
        "Stage III Bladder Cancer",
        "Stage III Urethral Cancer",
        "Stage IV Bladder Cancer",
        "Stage IV Urethral Cancer",
        "Transitional Cell Carcinoma of the Bladder",
        "Ureter Cancer"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2003-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-05",
      "last_synced_at": "2026-07-22T08:13:30.910Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00072150"
    },
    {
      "nct_id": "NCT03682068",
      "title": "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Unresectable Locally Advanced Urothelial Cancer",
        "Metastatic Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin + Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 1246,
      "start_date": "2018-09-27",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-28",
      "last_synced_at": "2026-07-22T08:13:30.910Z",
      "location_count": 23,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Fullerton, California + 19 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Salinas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682068"
    },
    {
      "nct_id": "NCT03170960",
      "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Renal Cell Carcinoma",
        "Non-Small Cell Lung Cancer",
        "Castration-resistant Prostate Cancer",
        "Triple Negative Breast Cancer",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Hepatocellular Carcinoma",
        "Gastric Cancer",
        "Gastroesophageal Junction Adenocarcinoma",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Differentiated Thyroid Cancer",
        "Lower Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 914,
      "start_date": "2017-09-05",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-17",
      "last_synced_at": "2026-07-22T08:13:30.910Z",
      "location_count": 57,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03170960"
    },
    {
      "nct_id": "NCT02834013",
      "title": "Nivolumab and Ipilimumab in Treating Patients With Rare Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acinar Cell Carcinoma",
        "Adenoid Cystic Carcinoma",
        "Adrenal Cortical Carcinoma",
        "Adrenal Gland Pheochromocytoma",
        "Anal Canal Neuroendocrine Carcinoma",
        "Anal Canal Undifferentiated Carcinoma",
        "Angiosarcoma",
        "Apocrine Neoplasm",
        "Appendix Mucinous Adenocarcinoma",
        "Bartholin Gland Transitional Cell Carcinoma",
        "Basal Cell Carcinoma",
        "Bladder Adenocarcinoma",
        "Breast Metaplastic Carcinoma",
        "Cervical Adenocarcinoma",
        "Cholangiocarcinoma",
        "Chordoma",
        "Colorectal Squamous Cell Carcinoma",
        "Desmoid Fibromatosis",
        "Endometrial Transitional Cell Carcinoma",
        "Endometrioid Adenocarcinoma",
        "Esophageal Neuroendocrine Carcinoma",
        "Esophageal Undifferentiated Carcinoma",
        "Extrahepatic Bile Duct Carcinoma",
        "Extramammary Paget Disease",
        "Fallopian Tube Adenocarcinoma",
        "Fallopian Tube Transitional Cell Carcinoma",
        "Fibromyxoid Tumor",
        "Gallbladder Carcinoma",
        "Gastric Neuroendocrine Carcinoma",
        "Gastric Squamous Cell Carcinoma",
        "Gastric Undifferentiated Carcinoma",
        "Gastrointestinal Stromal Tumor",
        "Gestational Trophoblastic Tumor",
        "Giant Cell Carcinoma",
        "Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type",
        "Intestinal Neuroendocrine Carcinoma",
        "Intrahepatic Cholangiocarcinoma",
        "Lung Neuroendocrine Tumor",
        "Lung Sarcomatoid Carcinoma",
        "Major Salivary Gland Carcinoma",
        "Malignant Neoplasm of Unknown Primary",
        "Malignant Odontogenic Neoplasm",
        "Malignant Peripheral Nerve Sheath Tumor",
        "Malignant Solid Neoplasm",
        "Malignant Testicular Sex Cord-Stromal Tumor",
        "Metastatic Pituitary Neuroendocrine Tumor",
        "Minimally Invasive Lung Adenocarcinoma",
        "Mixed Mesodermal (Mullerian) Tumor",
        "Mucinous Adenocarcinoma",
        "Mucinous Cystadenocarcinoma",
        "Nasal Cavity Adenocarcinoma",
        "Nasal Cavity Carcinoma",
        "Nasopharyngeal Carcinoma",
        "Nasopharyngeal Low Grade Papillary Adenocarcinoma",
        "Nasopharyngeal Undifferentiated Carcinoma",
        "Oral Cavity Carcinoma",
        "Oropharyngeal Undifferentiated Carcinoma",
        "Ovarian Adenocarcinoma",
        "Ovarian Germ Cell Tumor",
        "Ovarian Mucinous Adenocarcinoma",
        "Ovarian Squamous Cell Carcinoma",
        "Ovarian Transitional Cell Carcinoma",
        "Pancreatic Acinar Cell Carcinoma",
        "Pancreatic Neuroendocrine Carcinoma",
        "Paraganglioma",
        "Paranasal Sinus Adenocarcinoma",
        "Paranasal Sinus Carcinoma",
        "Parathyroid Gland Carcinoma",
        "PEComa",
        "Penile Squamous Cell Carcinoma",
        "Peritoneal Mesothelial Neoplasm",
        "Placental Choriocarcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Pseudomyxoma Peritonei",
        "Rare Disorder",
        "Scrotal Squamous Cell Carcinoma",
        "Seminal Vesicle Adenocarcinoma",
        "Seminoma",
        "Serous Cystadenocarcinoma",
        "Small Intestinal Adenocarcinoma",
        "Small Intestinal Squamous Cell Carcinoma",
        "Spindle Cell Neoplasm",
        "Teratoma With Somatic-Type Malignancy",
        "Testicular Non-Seminomatous Germ Cell Tumor",
        "Thyroid Gland Carcinoma",
        "Tracheal Carcinoma",
        "Transitional Cell Carcinoma",
        "Ureter Adenocarcinoma",
        "Ureter Squamous Cell Carcinoma",
        "Urethral Adenocarcinoma",
        "Urethral Squamous Cell Carcinoma",
        "Vaginal Adenocarcinoma",
        "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified",
        "Vulvar Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 798,
      "start_date": "2017-01-30",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-07-22T08:13:30.910Z",
      "location_count": 1006,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 620 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02834013"
    },
    {
      "nct_id": "NCT03582475",
      "title": "Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Small Cell Neuroendocrine Carcinoma",
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Bladder Urothelial Carcinoma",
        "Metastatic Urethral Urothelial Carcinoma",
        "Prostate Carcinoma Metastatic in the Bone",
        "Prostate Neuroendocrine Neoplasm",
        "Prostate Small Cell Carcinoma",
        "Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8",
        "Stage III Prostate Cancer AJCC v8",
        "Stage III Urethral Cancer AJCC v8",
        "Stage IV Bladder Cancer AJCC v8",
        "Stage IV Prostate Cancer AJCC v8",
        "Stage IV Urethral Cancer AJCC v8",
        "Stage IVA Bladder Cancer AJCC v8",
        "Stage IVB Bladder Cancer AJCC v8",
        "Ureter Small Cell Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2019-01-11",
      "completion_date": "2026-12-01",
      "has_results": true,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-07-22T08:13:30.910Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03582475"
    },
    {
      "nct_id": "NCT02643043",
      "title": "UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Bladder Cancer",
        "Urethral Cancer",
        "Cancer of the Ureter"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Matthew Milowsky, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2017-07-26",
      "completion_date": "2023-09-13",
      "has_results": false,
      "last_update_posted_date": "2023-09-29",
      "last_synced_at": "2026-07-22T08:13:30.910Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02643043"
    }
  ]
}